However, the TNM staging system is rather unreliable in predicting prognosis and is, therefore, often combined with biological markers to further subdivide the cancer, such as prostate-specific antigen (PSA) in prostate cancer, estrogen receptor (ER), progesterone receptor (PR), and ErbB2 in breast cancer [26]. Here, EREG is linked to prostate cancer.